Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Directors Deals Ltd.
$12.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Erytech Pharma SA has its study results published and launches Phase II study in pancreas cancer


Tuesday, 7 Jan 2014 01:00am EST 

Erytech Pharma SA:Says its research and development teams have worked in collaboration with researchers at the MD Anderson Cancer Center in Houston at confirming the mode of action and the potential of ERYASP in other cancer indications.Says it was found and published in a high ranking peer reviewed journal that 50 percent to 90 percent of known solid tumors are eligible for treatment through the concept of tumor starvation by administration of asparaginase.Says the company has demonstrated that solid tumors such as pancreatic, liver, bladder and ovarian cancer are potentially sensitive to an asparaginase-based treatment.Decides to continue the development in solid tumors by performing a Phase II study in second line pancreas cancer.Says it that study of about 100 patients, ERYASP in addition to the best standard of care will be compared to the best standard of care alone in a 2-to 1 randomization.Says scientific advice has been obtained from the European Medicines Agency (EMA) and a clinical trial application (CTA) has subsequently been submitted to the ANSM, the French authority for drug safety.